Stock listing
ANTX Stock Price, News, Filings & Events — An2 Therapeutics, Inc.
Selected listing: ANTX · NASDAQ · USD · US
This page tracks An2 Therapeutics, Inc.'s ANTX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ANTX:NASDAQ. ANTX:NASDAQ is the stock-level entry point for investors researching An2 Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. An2 Therapeutics, Inc. is a public company trading under the ticker ANTX in the American market. The company has a market capitalization of approximately $168.6 million. An2 Therapeutics focuses on developing innovative therapies to address unmet medical needs.

- Ticker
- ANTX:NASDAQ
- Asset type
- Stock
- Market cap
- $204.2M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
An2 Therapeutics, Inc. ANTX:NASDAQ stock context
This page tracks An2 Therapeutics, Inc.'s ANTX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ANTX:NASDAQ. ANTX:NASDAQ is the stock-level entry point for investors researching An2 Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. An2 Therapeutics, Inc. is a public company trading under the ticker ANTX in the American market. The company has a market capitalization of approximately $168.6 million. An2 Therapeutics focuses on developing innovative therapies to address unmet medical needs.
Latest news from An2 Therapeutics, Inc.
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of ...
August 31, 2026
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
August 24, 2026
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
August 11, 2026
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
June 4, 2026
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
May 21, 2026
Research An2 Therapeutics, Inc.
An2 Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for ANTX:NASDAQ.
An2 Therapeutics, Inc. company profile
View the public company page for An2 Therapeutics, Inc. on 6ix.
An2 Therapeutics, Inc. news
Read company news and market updates connected to An2 Therapeutics, Inc..
An2 Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for An2 Therapeutics, Inc..